LH vs NAMS: fair value comparison
Labcorp Holdings Inc. and NewAmsterdam Pharma Company N.V. · Updated 2026-10-19
NAMS has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, LH currently ranks higher by quality score.
| LH | NAMS | |
|---|---|---|
| Verdict | Fairly valued | No estimate yet |
| Last price | $312.15 | $19.83 |
| 12-month range | $246.64–$339.34 | $19.83–$41.45 |
| Rank by discount to fair value | #69 of 108 Healthcare | — |
| Rank by quality score | #136 of 301 Healthcare | #137 of 301 Healthcare |
| Quality grade | D | D |
| Leverage | Moderate | Low |
| Margin trend | Stable | Contracting |
| Revenue growth | Modest | Modest |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | — | Downtrend |
| DCF cross-check | Overvalued | — |
| 52-week position | The upper-middle quarter | The bottom quarter |
Full single-stock breakdowns: LH fair value analysis · NAMS fair value analysis